Navigation Links
Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina

          - Company files to deregister Common Stock with the SEC -
       - Canadian public listing on TSX Venture Exchange unaffected by
                   postponement of plans for U.S. listing -

    TSX Venture Exchange: NVC

VANCOUVER, June 25 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), today announced that it has voluntarily filed a Form 15 with the U.S. Securities and Exchange Commission ("SEC") in order to deregister its common stock under the United States Securities Exchange Act of 1934. As a result, effective immediately, Neovasc's obligation to file annual reports and furnish other information under the Exchange Act is suspended. The company's decision to deregister its Exchange Act registration is part of its larger plan to reduce discretionary expenses and allocate the cost savings to the further development and commercialization of its highest potential products. Neovasc will continue to undertake all activities required to maintain its Canadian public listing on the TSX Venture Exchange.

The company's decision to postpone its plans for a U.S. listing is based upon the additional financial and administrative costs and burdens associated with being a publicly traded company in the U.S. and therefore subject to the additional reporting regulations promulgated under the Exchange Act. Neovasc estimates the costs savings from suspending its planned listing to be approximately $200,000 annually. The company intends to redirect these funds to its program to commercialize the Neovasc Reducer(TM) for the treatment of refractory angina and to further expansion of the company's custom tissue business.

The SEC has 90 days to review the company's Form 15 for compliance with the decertification requirements. However, effective immediately, as a result of the filing of the Form 15, the company is no longer required to file annual reports under the Exchange Act on Form 20-F, or to furnish quarterly or other reports under the Exchange Act on Form 6-K. In addition, certain requirements of the Sarbanes Oxley Act of 2002 will no longer apply to the company. The company is eligible to deregister under the Exchange Act because its common stock is held of record by fewer than 300 persons. In addition, there is no established market for the company's common shares in the United States.

About Neovasc Inc.

Neovasc Inc. is a new specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer(TM), a novel product in development to treat refractory angina, as well as a line of advanced biological tissue technologies that are used to enhance surgical outcomes and as key components in a variety of third party medical products. For more information, visit:

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release include the Company's intention to redirect any cost savings that it may realize from deregistration to further development of the Neovasc Reducer. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. There can be no assurance that all of the anticipated cost savings can be applied to further development to the Neovasc Reducer. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.

SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neovasc Inc. Reports First Quarter 2009 Financial Results
2. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
3. Neovasc Completes $2 Million Non-Brokered Private Placement
4. Neovasc Inc. Reports Year 2008 Financial Results
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
7. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
8. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
9. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
10. American Pacific Postpones Fiscal 2009 Second Quarter Earnings Release and Investor Teleconference
11. President Obama Gives the Unborn at Least a 24 Hour Reprieve, Postpones $441 Million Bailout of International Abortions, Says Family Research Council
Post Your Comments:
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... Spokane, WA (PRWEB) , ... December 01, 2015 ... ... announced today that it has been selected as a finalist in this year’s ... FierceHealthcare, and FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Magazine as a Modern Man for 2015. , Angeleno Magazine is a ... United States. Established in 1994, Modern Luxury includes more than 50 magazine titles ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... ALBANY, New York , December 1, ... (Oral Contraceptive Pills, Contraceptive Injectables, Topical Contraceptives, ... Contraceptive Implants, Contraceptive Vaginal Rings, Contraceptive Diaphragms, ... Global Industry Analysis, Size, Share, Growth, Trends ... been released by Transparency Market Research (TMR).The ...
Breaking Medicine Technology: